Test Price
2,800 AED✅ Home Collection Available
TGFBR2 Gene Aortic Aneurysm, Familial Thoracic Type 3 Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
This advanced laboratory test delivers diagnostic accuracy exceeding 99.9 % through ISO-accredited next-generation sequencing of the TGFBR2 gene, providing definitive genetic risk assessment for familial thoracic aortic aneurysm type 3. The test includes temperature-controlled cold-chain home collection via VIP mobile phlebotomy and a telephonic post-result clinical guidance session with a consultant medical geneticist.
- Accuracy Guarantee: 99.9 % diagnostic sensitivity via ISO 15189 accredited processing with full gene coverage including deep intronic regions and CNV detection.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test clinical guidance session for comprehensive result interpretation and family cascade screening recommendations.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The TGFBR2 Gene Aortic Aneurysm, Familial Thoracic Type 3 Genetic Test is a state-of-the-art next-generation sequencing analysis that detects pathogenic and likely pathogenic variants in the TGFBR2 gene. Pathogenic variants in TGFBR2 are associated with familial thoracic aortic aneurysm type 3, a condition predisposing individuals to aortic root dilation, dissection, and sudden cardiac events. This comprehensive genetic assessment delivers precise, actionable insights to guide early cardiovascular intervention, personalised lifelong surveillance, and informed family planning.
| Feature | Our TGFBR2 NGS Test | Traditional Sanger Sequencing (Closest Alternative) |
|---|---|---|
| Precision | 99.9 % diagnostic sensitivity – complete gene coverage including deep intronic variants, splice-site variants, and large deletions/duplications via CNV analysis. | ~95 % sensitivity – limited to coding exons; may miss mosaic variants, deep intronic mutations, and large structural rearrangements. |
| Methodology | Next-Generation Sequencing (NGS) with high-depth coverage (minimum 100x) and integrated CNV detection pipeline. | Sanger sequencing of individual amplicons; no CNV analysis capability. |
| Turnaround Time | 3 – 4 Weeks | 2 – 3 Weeks (significantly less informative yield) |
Physician Insight & Safety Protocols
From Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403:
“A positive TGFBR2 result indicates a substantially elevated lifetime risk for thoracic aortic aneurysm, not an inevitable outcome. Comprehensive clinical correlation with echocardiographic imaging, family pedigree analysis, and blood pressure management is essential. Our multidisciplinary approach ensures that every patient receives compassionate counselling, clear risk stratification, and a tailored surveillance protocol grounded in the latest international guidelines.”
Medication Advisory
Important Medication Safety Notice
Do not discontinue, adjust, or alter any prescribed antihypertensive or cardiovascular medication without explicit consultation with your treating physician. Abrupt cessation of beta-blockers or angiotensin receptor blockers may precipitate acute aortic complications.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Individuals unable to provide informed consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Minors without legal guardian consent as per UAE Federal Law.
- Uncontrolled psychiatric conditions that may interfere with result interpretation or genetic counselling engagement.
Seek Immediate Emergency Care if You Experience:
- Sudden, severe chest or back pain (tearing or ripping sensation).
- Shortness of breath or difficulty breathing.
- Fainting, syncope, or loss of consciousness.
- Signs suggestive of aortic dissection including pulse deficit or neurological deficit.
Patient FAQ & Clinical Guidance
1. What is the TGFBR2 gene test for familial thoracic aortic aneurysm type 3?
This targeted genetic test identifies disease-causing variants in the TGFBR2 gene that are associated with familial thoracic aortic aneurysm type 3. The result provides a precise genetic risk assessment to guide early cardiovascular monitoring, prophylactic surgical planning, and cascade screening of at-risk family members.
2. How is the test performed and what sample is required?
A standard peripheral whole blood sample (5–10 mL) is collected by a certified phlebotomist via venipuncture. The specimen is transported under temperature-controlled cold-chain conditions to our ISO-accredited laboratory for high-depth next-generation sequencing analysis.
3. How long does it take to receive results and what support is provided?
Results are available within 3 to 4 weeks from sample receipt. Every patient receives a telephonic post-test clinical guidance session with a consultant medical geneticist to comprehensively interpret the report, discuss implications for family members, and coordinate referral to cardiovascular specialists as needed.
UAE Regulatory & Data Privacy Adherence
Data Protection & Healthcare Compliance Framework
All genetic data and personal health information are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Your genetic results are encrypted, access-controlled, and never shared with third parties without your explicit written consent. You retain full rights to access, rectify, and request deletion of your data under PDPL Article 14.
Clinical & Logistical Metadata
| Test Name | TGFBR2 Gene Aortic Aneurysm, Familial Thoracic Type 3 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (5–10 mL) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM – 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) with high-depth coverage and CNV detection |
| ICD-10-CM Code | I71.2 |
| LOINC Code | 81408-6 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians